TMED7-TICAM2

Across TCGA pan-cancer cohorts, TMED7-TICAM2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated TMED7-TICAM2 data layer compared with 6 for mutation status.

The strongest signal is observed in uveal melanoma (UVM), where higher TMED7-TICAM2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMED7-TICAM2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and ACC show a favorable association.

UVM, LUAD, and KICH are the cancer types where TMED7-TICAM2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Tertile	All	0.282	0.753	<.001	111	view →
LUAD	OS	Tertile	All	0.264	0.467	<.001	101	view →
KICH	DFS	Tertile	II,III,IV	0.451	0.944	.001	74	view →
CESC	OS	Median	All	0.431	0.731	<.001	70	view →
HNSC	OS	Quartile	All	0.685	0.818	.002	51	view →
BRCA	OS	Median	All	0.898	0.945	<.001	50	view →
LGG	OS	Median	All	0.366	0.525	<.001	50	view →
LIHC	OS	Median	All	0.707	0.839	<.001	40	view →
THCA	OS	Median	All	0.959	1.000	.006	28	view →
KIRC	DFS	Quartile	II,III,IV	0.803	0.536	.020	18	view →
ACC	OS	Tertile	IV	0.884	0.260	.024	12	view →
LUSC	OS	Tertile	All	0.347	0.510	.032	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

TMED7-TICAM2–UVM (DFS)

Open the UVM breakdown →